Table 3 Primary and secondary endpoints

Complete remission

6 months, n (%)

5/86 (5.8)

3/86 (3.5)

2/86 (2.3)

12 months, n (%)

5/65 (7.7)

11/66 (16.7)

9/74 (12.2)

End of follow-up, n (%)

11/86 (12.8)

18/86 (20.9)

18/86 (20.9)

Total remission

6 months, n (%)

27/86 (31.4)

33/86 (38.4)

31/86 (36)

12 months, n (%)

25/65 (38.5)

36/66 (54.5)

51/74 (68.9)**

End of follow-up, n (%)

39/86 (45.3)

47/86 (54.7)

59/86 (68.6)**

Relapse

Relapse, n (%)

15/39 (38.5)

2/47 (4.3)**

2/59 (3.4)**

Relapse-free survival time, mo

11.6 ± 8.1

3, 21^a

12, 21^a

Renal function decline

≥ 25% decline in eGFR, n (%)

31/86 (36)

14/86 (16.3)**

8/86 (9.3)**

ESRD/dialysis, n (%)

4/86 (4.7)

3/86 (3.5)

0